Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Internationally Recognized Certificates of Compliance
(IRCC)
last updated: 17 Apr 2018
ABSCH-IRCC-IN-239854-1
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
India/NBA/Appl/9/1551
Application in Form-III for seeking approval for the invention “Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma” for obtaining IP Rights in Canada, Spain, France , United Kingdom, Republic of Korea, Switzerland, Italy, Australia, India, Japan, United States of America, China and Germany.
Indian Patent Application Number: 201641018401
Indian Patent Application Number: 201641018401
09 Jan 2018
Yes
Competent National Authority:National Biodiversity Authority ()5th Floor, TICEL Biopark, CSIR Road, TaramaniChennai, Tamilnadu
600 113, IndiaPhone: +91 44 2254 2777,Fax: +91 44 2254 1200,Website: http://www.nbaindia.org,
Confidential information
Person:Dr E. SreekumarChief Scientific Officer,Phone: +91 9447698943,Fax:Email: esreekumar@rgcb.res.in,Website:Related OrganizationRajiv Gandhi Centre for Biotechnology (RGCB)Academic or research institutePoojappuraThiruvananthapuram, Kerala
695014, IndiaPhone: +91 471 2529419,Fax:Email: director@rgcb.res.in,Website:
-
Organization:
Rajiv Gandhi Centre for Biotechnology
(RCGB)
|
ABSCH-CON-IN-239778-1
This document has been updated. This is not the latest published version.
Click here to view the latest version of the record.
Organization:Rajiv Gandhi Centre for Biotechnology (RCGB)Academic or research institutePoojappuraThiruvananthapuram:, Kerala
695014, IndiaPhone: +91 471 2529419,Fax:Email: director@rgcb.res.in,Website:
Confidential information
Yes
1. The user shall notify the NBA within 60 days from the date of grant of IPR and also assignment or
licence of the IPR to any person, if any.
licence of the IPR to any person, if any.
2. If the user himself commercializes the process/product/innovation, the monetary sharing shall be
0.2% on the annual gross ex-factory sale minus government taxes.
0.2% on the annual gross ex-factory sale minus government taxes.
3. The user needs to inform the NBA about any commercialization made on the IP Rights granted
within 45 days from the date of such event.
within 45 days from the date of such event.
4. The user shall submit annual report to NBA as per the terms and conditions agreed upon.
For obtaining IP Rights on the Invention “Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma” for obtaining IP Rights in Canada, Spain, France, United Kingdom, Republic of Korea, Switzerland, Italy, Australia, India, United States of America, Japan, China and Germany.
Biological Resources:
Black nightshade - Solanum nigrum
Confidential information
- Commercial
1. If the user assigns/licenses the process/product/innovation to a third party for commercialization, the user shall pay to NBA 3.0% of the fee received (in any form including the license / assignee fee) and 2.0% of the royalty amount received annually from the assignee/licensee.
2. In case the user assigns or transfers the IPR to any person, the user undertakes to attach this agreement as an appendix to the assignment instrument which shall be binding upon such person, and inform the NBA within 60 days from the date of such transfer.
| Unique identifier | Status | Date |
|---|---|---|
| ABSCH-IRCC-IN-239854-1 |
REVOKED
OLD VERSION
PUBLISHED
DELETED
|
Sujata Arora (sujata@nic.in)
17 Apr 2018 07:21 on 17 Apr 2018 07:21
|
